Clinical Trials
48
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (48 trials with phase data)• Click on a phase to view related trials
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis (MS) Primary Progressive
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 705
- Registration Number
- NCT07067463
ICP-332 in Subjects With Non-segmental Vitiligo
- Conditions
- Non Segmental Vitiligo
- Interventions
- Drug: ICP-332 TabletsDrug: ICP-332 Placebo Tablets
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 603
- Registration Number
- NCT07047612
- Locations
- 🇨🇳
The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Relapsed or Refractory Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT06845241
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fu zhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hosptital, Zhengzhou, Henan, China
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis Patients
- Interventions
- Drug: ICP-488 TabletsDrug: ICP-488 Placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06842199
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Beijing Chao-Yang Hospital，Capital Medical University, Beijing, Beijing, China
ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ICP-332 TabletsDrug: ICP-332 Placebo Tablets
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 552
- Registration Number
- NCT06775860
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Capital Medical University Affiliated Beijing Chaoyang Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next